Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 65 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Wegeners Granulomatosis (Granulomatosis With Polyangiitis) Clear all
Completed No phase listed Observational

Educational Needs of Patients With Systemic Vasculitis

NCT02190929
View directory record Official record
Conditions
Behcet's Disease, Churg-Strauss Syndrome, Vasculitis, Central Nervous System, Giant Cell Arteritis, Wegener Granulomatosis, Henoch-Schoenlein Purpura, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu's Arteritis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Oct 22, 2026, 1:36 AM EDT
Completed No phase listed Observational

Journey of Patients With Vasculitis From First Symptom to Diagnosis

NCT03410290
View directory record Official record
Conditions
Vasculitis, Systemic Vasculitis, Behcet's Disease, CNS Vasculitis, Cryoglobulinemic Vasculitis, Eosinophilic Granulomatous Vasculitis, Temporal Arteritis, Giant Cell Arteritis, Granulomatosis With Polyangiitis, Wegener Granulomatosis, Henoch Schonlein Purpura, IgA Vasculitis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis, Urticarial Vasculitis
Interventions
Online Questionnaire
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 22, 2026, 1:36 AM EDT
Completed No phase listed Observational

Reproductive Health in Men and Women With Vasculitis

NCT02176070
View directory record Official record
Conditions
Giant Cell Arteritis, Takayasu's Arteritis, Polyarteritis Nodosa, Wegener's Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Behcet's Disease, Kawasaki Disease, Henoch-schoenlein Purpura, Vasculitis, Central Nervous System, Drug-induced Necrotizing Vasculitis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 22, 2026, 1:36 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

NCT05263934
View directory record Official record
Conditions
Eosinophilic Granulomatosis With Polyangiitis
Interventions
Depemokimab, Mepolizumab, Placebo matching mepolizumab, Placebo matching depemokimab
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Denver, Colorado • Gainesville, Florida • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 22, 2026, 1:36 AM EDT
Recruiting Phase 2Phase 3 Interventional

TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis

NCT07176546
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Wegener's, GPA
Interventions
Avacopan, Placebo
Drug
Lead sponsor
Robert Spiera, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Edison, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 22, 2026, 1:36 AM EDT
Completed Phase 3 Interventional Results available

Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921

NCT03298061
View directory record Official record
Conditions
Churg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis
Interventions
Mepolizumab, Prednisolone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
14
States / cities
Denver, Colorado • Bethesda, Maryland • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 22, 2026, 1:36 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA

NCT03712345
View directory record Official record
Conditions
Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA)
Interventions
IFX-1 low dose, IFX-1 high dose, Placebo
Drug
Lead sponsor
InflaRx GmbH
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
33
States / cities
Scottsdale, Arizona • Loma Linda, California • Doral, Florida + 30 more
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 22, 2026, 1:36 AM EDT
Recruiting Phase 2 Interventional

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NCT07138898
View directory record Official record
Conditions
Rheumatic Disease
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
Drug · Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 22, 2026, 1:36 AM EDT
Recruiting No phase listed Observational

One-Time DNA Study for Vasculitis

NCT01241305
View directory record Official record
Conditions
Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Giant Cell Arteritis, Granulomatosis With Polyangiitis (Wegener's), Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu's Arteritis
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
7 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2028
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 22, 2026, 1:36 AM EDT
Terminated Phase 2 Interventional Results available

PR3-AAV Resilient Remission or PRRR

NCT05376319
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Microscopic Polyangiitis, ANCA Associated Vasculitis
Interventions
Obinutuzumab, Rituximab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Boston, Massachusetts • Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 22, 2026, 1:36 AM EDT
Completed Phase 2 Interventional

Steroids and Methotrexate to Treat Systemic Vasculitis

NCT00001256
View directory record Official record
Conditions
Inflammation, Vasculitis, Wegener's Granulomatosis
Interventions
prednisone and methotrexate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 1:36 AM EDT
Completed Phase 2 Interventional

Etanercept to Treat Wegener's Granulomatosis

NCT00001901
View directory record Official record
Conditions
Vasculitis, Wegener's Granulomatosis
Interventions
Etanercept
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 1:36 AM EDT
Terminated Phase 4 Interventional

Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis

NCT02626845
View directory record Official record
Conditions
Granulomatosis With Polyangiitis (Wegener's Granulomatosis)
Interventions
Rituximab, Placebo
Drug · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Oct 22, 2026, 1:36 AM EDT
Recruiting Phase 3 Interventional

A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases

NCT06512883
View directory record Official record
Conditions
Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES)
Interventions
Benralizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Aurora, Colorado • Cincinnati, Ohio • Highland Hills, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 22, 2026, 1:36 AM EDT
Completed Phase 2 Interventional

Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis

NCT03482479
View directory record Official record
Conditions
Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Giant Cell Arteritis, Granulomatosis With Polyangiitis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis
Interventions
Naltrexone Hydrochloride, Placebo Comparator
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
6
States / cities
Boston, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 22, 2026, 1:36 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis

NCT02020889
View directory record Official record
Conditions
Churg-Strauss Syndrome
Interventions
Mepolizumab, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Denver, Colorado • Bethesda, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Oct 22, 2026, 1:36 AM EDT
Completed Phase 4 Interventional Results available

Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis

NCT02169219
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Interventions
Glucocorticoids, Rituximab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 22, 2026, 1:36 AM EDT
Recruiting No phase listed Observational

Clinical Transcriptomics in Systemic Vasculitis (CUTIS)

NCT03004326
View directory record Official record
Conditions
Cryoglobulinemic Vasculitis (CV), Drug-induced Vasculitis, Eosinophilic Granulomatosis With Polyangiitis (EGPA), IgA Vasculitis, Isolated Cutaneous Vasculitis, Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA), Polyarteritis Nodosa (PAN), Urticarial Vasculitis, Vasculitis
Interventions
Not listed
Lead sponsor
Peter Merkel
Other
Eligibility
5 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
8
States / cities
Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 22, 2026, 1:36 AM EDT
Completed Phase 3 Interventional Results available

Belimumab in Remission of VASculitis

NCT01663623
View directory record Official record
Conditions
Vasculitis
Interventions
Placebo, Belimumab 10 mg/kg, Azathioprine
Biological · Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 22, 2026, 1:36 AM EDT
Recruiting No phase listed Observational

Vasculitis Pregnancy Registry

NCT02593565
View directory record Official record
Conditions
Vasculitis, Behcet's Disease, CNS Vasculitis, Cryoglobulinemic Vasculitis, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Granulomatosis With Polyangiitis (GPA), Wegener's Granulomatosis, IgA Vasculitis, Henoch-Schoenlein Purpura (HSP), Microscopic Polyangiitis (MPA), Polyarteritis Nodosa (PAN), Takayasu Arteritis (TAK), Urticarial Vasculitis, Systemic Vasculitis
Interventions
Online questionnaires
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 22, 2026, 1:36 AM EDT
Recruiting No phase listed Observational

Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis

NCT00315380
View directory record Official record
Conditions
Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2028
U.S. locations
8
States / cities
San Diego, California • Denver, Colorado • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 22, 2026, 1:36 AM EDT
Active, not recruiting Phase 2 Interventional

Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

NCT03010436
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Oct 22, 2026, 1:36 AM EDT
Terminated Phase 4 Interventional Results available

Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")

NCT00747461
View directory record Official record
Conditions
Lung Diseases, Obstructive, Sarcoidosis, Wegener's Granulomatosis, Rhinoscleroma, Recurrent Respiratory Papillomatosis
Interventions
CryoSpray Ablation
Device
Lead sponsor
CSA Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Oct 22, 2026, 1:36 AM EDT
Completed No phase listed Observational

Analysis of Bronchial Tissue and Fluid in Patients With Wegener's Granulomatosis

NCT00001541
View directory record Official record
Conditions
Inflammation, Vasculitis, Wegener's Granulomatosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 1:36 AM EDT